Scientific Research News

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, com...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “The recent expansion of our T...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel’s potential to be a life-changing therapy for mu...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer’s disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, for patients being evaluated for cognitive complaints through a simpl...

ANNAPOLIS, Md.--(BUSINESS WIRE)--In celebration of International Cat Day celebrated annually on August 8th, CATalyst Council announces the next phase of its ongoing commitment to advancing the feline veterinary market, closing the feline care gap, and reshaping the future of cat-centered care across the animal health ecosystem: a nationwide, 40,000-household survey study. The study is designed to generate a high confidence understanding of the emotional, behavioral, and psychological factors in...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab and lenalidomide (R2) versus R2 alone for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study met its dual primary endpoints of overall response rate (ORR, p-value < 0.0001) and progression-free survival (PFS, HR 0.21, p-valu...

ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). EB Simplex is a rare, inherited skin disorder that causes painful blistering...

DETROIT--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, will convene breast cancer survivors, those living with metastatic breast cancer (MBC) and supporters at the 2025 Susan G. Komen Detroit Race for the Cure. This impactful event unites our community and raises money for the mission of Komen, supporting those affected by breast cancer. Komen aims to raise over $300,000 at the Detroit Race for the Cure, generating critical funds that allow Komen to continue...

SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about Earth, today announced that it will participate in Morgan Stanley’s 13th Annual Laguna Conference, which is being held September 10-12, 2025. The company will be available for 1x1 meetings with investors. If interested in attending this event or scheduling a meeting with management, we recommend reaching out to your contact at Morgan Stanley to learn more. About Planet Planet is a lea...